ham. I might agree with you if they weren't already selling Lovaza . Its basically the same market ( over half of Lovaza was prescribed off label for CV risk reduction according to last GSK data I saw ) .......so they faze out G Lovaza and replace with G Vascepa ...same sales channel etc .
Vascepa is a growing market ..vs Copaxone which I think is declining ...so for that reason I think they have to be there Kiwi
2019
Teva predicts bleak year ahead as generic, Copaxone sales drop
News 
Market Data 
Discover 
AI
